Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Currently, acute allograft rejection can only be detected reliably by deterioration of graft function confirmed by allograft biopsy. A huge drawback of this method of diagnosis is that substantial organ damage has already taken place at the time that rejection is diagnosed. Discovering and validating noninvasive biomarkers that predict acute rejection, and chronic allograft dysfunction, is of great importance. Many studies have investigated changes in the peripheral blood in an attempt to find biomarkers that reflect changes in the graft directly or indirectly. Herein, we will review the promises and limitations of the peripheral blood biomarkers that have been described in the literature so far.

Original publication

DOI

10.1097/TP.0b013e318218e978

Type

Journal article

Journal

Transplantation

Publication Date

15/07/2011

Volume

92

Pages

1 - 9

Keywords

Acute Disease, Antigens, CD30, Biomarkers, Chemokines, Chronic Disease, Endothelial Cells, Flow Cytometry, Gene Expression Profiling, Graft Rejection, Humans, Interferon-gamma, Isoantibodies, Lymphocyte Activation, MicroRNAs, Monitoring, Immunologic, Transplantation Immunology